OneTouch Ultra Plus Flex Blood Glucose Monitoring System
Device Facts
| Record ID | K151611 |
|---|---|
| Device Name | OneTouch Ultra Plus Flex Blood Glucose Monitoring System |
| Applicant | Lifescan Europe |
| Product Code | NBW · Clinical Chemistry |
| Decision Date | Dec 14, 2015 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 862.1345 |
| Device Class | Class 2 |
| Attributes | Pediatric |
Indications for Use
The OneTouch Ultra Plus Flex Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertip. The OneTouch Ultra Plus Flex Blood Glucose Monitoring System is intended to be used by a single patient and should not be shared. OneTouch Ultra Plus Flex Blood Glucose Monitoring System is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The OneTouch Ultra Plus Flex Blood Glucose Monitoring System is not to be used for the diagnosis of or screening of diabetes, or for neonatal use. The OneTouch Ultra Plus Test Strips are for use with the OneTouch Ultra Plus Flex Blood Glucose Meter to quantitatively measure glucose drawn from the fingertips.
Device Story
System measures glucose in fresh capillary whole blood samples via test strips; utilizes amperometric electrochemical reaction. User applies blood to strip; meter processes electrical current to calculate glucose concentration. Designed for single-patient home use; operated by patient. Includes meter, test strips, control solutions, lancing device, and sterile lancets. Features wireless communication and range indicator software. Output displayed on meter screen; assists patients in monitoring diabetes control effectiveness. Benefits include convenient, accurate self-monitoring of blood glucose levels.
Clinical Evidence
Clinical performance evaluated via user performance study with 169 lay users. Results compared to YSI reference method. For glucose < 75 mg/dL, 95% of results were within ±15 mg/dL. For glucose > 75 mg/dL, 100% of results were within ±20%. Linear regression showed slope 1.02, R² 0.99. Usability study confirmed labeling comprehension.
Technological Characteristics
Amperometric glucose monitoring system. Reagent: FAD-GDH, potassium ferricyanide. Power: 3V Li battery (CR2032). Connectivity: Bluetooth Low Energy, USB. Operating range: 10-40°C, 10-90% RH. Software: Gemini Blood Glucose algorithm. Sterilization: N/A (non-sterile device).
Indications for Use
Indicated for single-patient, home-use, in vitro diagnostic quantitative measurement of glucose in fresh capillary whole blood from the fingertip by people with diabetes to monitor diabetes control. Not for diagnosis, screening, or neonatal use.
Regulatory Classification
Identification
A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.
Special Controls
*Classification.* Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
Predicate Devices
- OneTouch® Verio™ Blood Glucose Monitoring System (K131363)
Related Devices
- K150214 — OneTouch Verio Flex Blood Glucose Monitoring System · Lifescan Europe · Jul 31, 2015
- K182286 — Oh'Care Lite Smart Blood Glucose Monitoring System · Osang Healthcare Co. , Ltd. · Sep 19, 2018
- K240637 — RIGHTEST Blood Glucose Monitoring System Max Tel · Bionime Corporation · Nov 4, 2024
Submission Summary (Full Text)
{0}
1
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY AND INSTRUMENT COMBINATION TEMPLATE
A. 510(k) Number:
k151611
B. Purpose for Submission:
New device
C. Measurand:
Whole blood glucose
D. Type of Test:
Quantitative, amperometric method, Glucose dehydrogenase (FAD)
E. Applicant:
LifeScan Europe
F. Proprietary and Established Names:
OneTouch Ultra Plus Flex Blood Glucose Monitoring System
G. Regulatory Information:
1. Regulation section:
21 CFR 862.1345, glucose test system
2. Classification:
Class II
3. Product code:
NBW
LFR
{1}
4. Panel:
Clinical Chemistry (75)
H. Intended Use:
1. Intended use(s):
See Indication(s) for use below.
2. Indication(s) for use:
The OneTouch Ultra Plus Flex Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertip. The OneTouch Ultra Plus Flex Blood Glucose Monitoring System is intended to be used by a single patient and should not be shared.
OneTouch Ultra Plus Flex Blood Glucose Monitoring System is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The OneTouch Ultra Plus Flex Blood Glucose Monitoring System is not to be used for the diagnosis of or screening of diabetes, or for neonatal use.
The OneTouch Ultra Plus Test Strips are for use with the OneTouch Ultra Plus Flex Blood Glucose Meter to quantitatively measure glucose drawn from the fingertips.
3. Special conditions for use statement(s):
For over-the-counter use
- The OneTouch Ultra Plus Flex™ Blood Glucose Monitoring System is intended to be used by a single patient and should not be shared.
- The OneTouch Ultra Plus Flex™ System is not to be used for the diagnosis or screening of diabetes or for neonatal use.
- The OneTouch Ultra Plus Flex™ System is not for use on critically ill patients, patients in shock, severely dehydrated patients or hyperosmolar patients (with or without ketosis).
- The OneTouch Ultra Plus Flex™ System is not recommended for alternate site testing (AST).
- The OneTouch Ultra Plus Flex™ Blood Glucose Monitoring System should not be used within 24 hours of receiving a D-xylose absorption test as it may cause inaccurately high results.
2
{2}
- Do Not use the OneTouch Ultra Plus Flex™ Meter when PAM (Pralidoxime) is known or suspected to be in the whole blood sample.
4. Special instrument requirements:
OneTouch Ultra Plus Flex Blood Glucose Meter
I. Device Description:
The OneTouch Ultra Plus Flex Blood Glucose Monitoring System consists of the following components:
- OneTouch Ultra Plus Flex Meter
- OneTouch Ultra Plus Level 3 Control Solution (available separately)
- OneTouch Ultra Plus Level 4 Control Solution (available separately)
- OneTouch Ultra Plus Test Strips (available separately)
- OneTouch Delica Lancing Device (or alternative Lancing Device)
- OneTouch Delica Sterile Lancets (or alternative sterile lancets)
- Carrying Case
- OneTouch Ultra Plus Flex Product Labeling (Owner's Manual and Quick Start Guide)
The OneTouch Ultra Plus Flex Blood Glucose Monitoring System can transmit blood glucose measurement data to a computer or mobile device via a Bluetooth Low Energy transmitter in the meter or via an external USB cable.
Each vial of test strips contains 50 test strips. Each test strip has the following reagent composition: Flavin adenine dinucleotide dependent glucose dehydrogenase (FAD-GDH) from Aspergillus sp. – 2 U; potassium ferricyanide 41μg; and other ingredients (buffer, etc.).
The OneTouch Ultra Plus Flex Control Solutions were previously cleared in k131363.
J. Substantial Equivalence Information:
1. Predicate device name(s):
OneTouch Verio Blood Glucose Monitoring System
2. Predicate 510(k) number(s):
k131363
{3}
3. Comparison with predicate:
| Item | Candidate Device OneTouch Ultra Plus Flex Blood Glucose Monitoring System | Predicate Device OneTouch Verio Blood Glucose Monitoring System (k131363) |
| --- | --- | --- |
| Indications for use | It is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood as an aid to monitor the effectiveness of diabetes control. | Same |
| Sample type | Whole capillary blood from fingertip | Whole capillary blood from fingertip, forearm, palm |
| Test strip used | OneTouch Ultra Plus Test Strips | OneTouch Verio Test Strips |
| Control solutions used | OneTouch Ultra Plus Level 3 and Level 4 Control Solutions | OneTouch Verio Level 3 and Level 4 Control Solutions |
| Detection method | Amperometric | Same |
| Enzyme | Flavin adenine dinucleotide dependent glucose dehydrogenase | Same |
| Sample volume | 0.4 μL | Same |
| Operating conditions | 50°F to 104°F (10°C to 40°C) and relative humidity between 10 to 90% R.H. | Same |
| HCT range | 20-60% | Same |
| Detection range | 20-600 mg/dL | Same |
| Measuring time | 5 seconds | Same |
| Power battery | 3V Li battery (CR2032) | Same |
| Memory storage | 500 control and glucose results | Same |
| Range Indicator | The device includes a monochrome arrow on the LCD display that will point to a pre-printed Red, Green, or Blue range indicator adjacent to the meter lens, corresponding to High, In Range, or Low indication of glucose test values | Not available |
{4}
| | compared to customer-selected target range values. | |
| --- | --- | --- |
| Data Download | USB or Bluetooth Low Energy transmitter | USB only |
| Compatible off-meter software accessories | OneTouch Diabetes Management Software, OneTouch Zoom Pro, OneTouch Reveal | OneTouch Diabetes Management Software |
| Software | Bias corrected Gemini Blood Glucose algorithm | Gemini Blood Glucose algorithm |
| | Manual sample tagging of sample type (blood vs. control solution) | Autodetection of sample type (blood vs. control solution) |
# K. Standard/Guidance Document Referenced (if applicable):
CLSI EP05-A2 "Evaluation of Precision Performance of Quantitative Measurement Methods"
CLSI EP06-A "Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach"
CLSI EP07-A2 "Interference Testing in Clinical Chemistry"
CLSI EP09-A2 "Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline"
# L. Test Principle:
The OneTouch Ultra Plus Flex Blood Glucose Monitoring System employs flavin adenine dinucleotide glucose dehydrogenase (FAD-GDH) enzyme chemistry as the standard dry reagent assay for glucose in whole blood. This enzyme assay, with a redox chemical "mediator" reaction, is used to generate an electrical current proportional to the glucose concentration in the blood sample. The system is designed as an amperometric measurement device using current generated from the redox reaction as the measurable response.
# M. Performance Characteristics (if/when applicable):
# 1. Analytical performance:
a. Precision/Reproducibility:
The sponsor performed repeatability (within-run) precision studies using venous
{5}
whole blood spiked to 7 different glucose concentration levels (15 to 25, 30 to 50, 51 to 110, 111 to 150, 151 to 250, 251 to 400, 570 to 630 mg/dL). Each glucose concentration level was analyzed in replicates of 10, with 3 test strip lots, and 10 meters, for a total of 300 tests per glucose level for each meter. Results are summarized below:
| Glucose Level, mg/dL | Strip Lot | n | Average Glucose mg/dL | SD, mg/dL | CV, % |
| --- | --- | --- | --- | --- | --- |
| 15-25 | 1 | 100 | 19.95 | 0.55 | 2.74 |
| | 2 | 100 | 19.35 | 0.51 | 2.63 |
| | 3 | 100 | 18.88 | 0.60 | 3.19 |
| | Combined | | | 0.55 | 2.86 |
| 30-50 | 1 | 100 | 35.07 | 0.84 | 2.40 |
| | 2 | 100 | 34.91 | 0.92 | 2.64 |
| | 3 | 100 | 34.97 | 0.82 | 2.34 |
| | Combined | | | 0.86 | 2.46 |
| 51-110 | 1 | 100 | 99.96 | 1.92 | 1.92 |
| | 2 | 100 | 98.76 | 1.88 | 1.91 |
| | 3 | 100 | 97.70 | 1.86 | 1.87 |
| | Combined | | | 1.89 | 1.91 |
| 111-150 | 1 | 100 | 135.45 | 2.53 | 1.87 |
| | 2 | 100 | 145.01 | 3.62 | 2.50 |
| | 3 | 100 | 137.33 | 2.55 | 1.85 |
| | Combined | | | 2.95 | 2.11 |
| 151-250 | 1 | 100 | 225.92 | 4.30 | 1.90 |
| | 2 | 100 | 219.48 | 4.30 | 1.96 |
| | 3 | 100 | 221.56 | 4.22 | 1.91 |
| | Combined | | | 4.28 | 1.92 |
| 251-400 | 1 | 100 | 394.41 | 8.25 | 2.09 |
| | 2 | 100 | 378.96 | 8.98 | 2.37 |
| | 3 | 100 | 373.09 | 7.07 | 1.89 |
| | Combined | | | 8.14 | 2.13 |
| 570-630 | 1 | 100 | 665.17 | 13.49 | 2.03 |
| | 2 | 100 | 625.42 | 12.93 | 2.07 |
| | 3 | 100 | 633.23 | 14.09 | 2.22 |
| | Combined | | | 13.51 | 2.11 |
{6}
Intermediate (between run) precision was evaluated using 5 levels of glucose control solutions (0 to 24, 25 to 49, 102 to 138, 298 to 403, 446 to 604 mg/dL) over 10 days with 3 test strip lots. For each level, on each day, 10 meters were used for testing, with 2 replicates collected per meter for a total of 20 replicates per day for each glucose level. Results are summarized below:
Intermediated precision:
| Glucose Level, mg/dL | Strip Lot | n | Average Glucose (mg/dL) | SD, mg/dL | CV, % |
| --- | --- | --- | --- | --- | --- |
| 0-24 | 1 | 200 | 12.57 | 0.46 | 3.70 |
| | 2 | 200 | 12.51 | 0.46 | 3.65 |
| | 3 | 200 | 12.09 | 0.47 | 3.92 |
| | Combined | | | 0.47 | 3.76 |
| 25-49 | 1 | 200 | 37.27 | 1.04 | 2.78 |
| | 2 | 200 | 36.55 | 0.92 | 2.52 |
| | 3 | 200 | 36.79 | 0.94 | 2.55 |
| | Combined | | | 0.97 | 2.62 |
| 102-138 | 1 | 200 | 119.09 | 2.30 | 1.94 |
| | 2 | 200 | 116.74 | 1.92 | 1.64 |
| | 3 | 200 | 118.11 | 2.34 | 1.98 |
| | Combined | | | 2.19 | 1.86 |
| 298-403 | 1 | 200 | 356.52 | 8.05 | 2.26 |
| | 2 | 200 | 347.51 | 7.78 | 2.24 |
| | 3 | 200 | 352.21 | 7.94 | 2.25 |
| | Combined | | | 7.92 | 2.25 |
| 446-604 | 1 | 200 | 523.95 | 14.58 | 2.78 |
| | 2 | 200 | 515.06 | 11.19 | 2.17 |
| | 3 | 200 | 522.68 | 11.78 | 2.25 |
| | Combined | | | 12.60 | 2.42 |
b. Linearity/assay reportable range:
Linearity testing was performed using venous whole blood samples from 9 donors. The evaluation was conducted with 8 meters and 3 test strip lots. Samples with the following glucose concentrations were prepared and confirmed by a laboratory
{7}
reference method (YSI): 22.07, 60.94, 101.0, 201.53, 301.71, 401.57, 504.63, 604.74, and 705.94 mg/dL. The study includes a total of 144 testing of samples per glucose concentration per test strip lot using 8 meters, and a total of N=432 measurements per glucose concentration with three test strip lots.
The evaluation yielded the following regression equation based on all samples:
| Lot | Slope | y-intercept | R² |
| --- | --- | --- | --- |
| 1 | 1.049 | -4.588 | 0.998 |
| 2 | 1.032 | -4.060 | 0.998 |
| 3 | 1.047 | -5.374 | 0.998 |
The results of the study support the sponsor's claimed glucose measuring range of 20 – 600 mg/dL.
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
The system is traceable to NIST SRM #917b reference material and calibrated to be plasma-equivalent.
**Test strip stability:**
Real time stability studies are ongoing to assess the shelf-life and open-vial stability of the OneTouch Ultra Plus Test strips. Real-time stability protocols and acceptance criteria were evaluated and found to be acceptable to support closed-vial stability of 12 months at 41-86°F (65% relative humidity) and open-vial stability of 6 months when test strips are stored at the recommended storage temperature range of 41-86°F and 65% relative humidity.
**Control Solution Value Assignment and Stability:**
The OneTouch Ultra Plus Control Solutions were previously cleared under k120708. Stability studies support a closed-vial shelf life of 24 months and an open-vial shelf life of 6 months when stored at 41-86°F.
d. Detection limit:
The reportable range for the OneTouch Ultra Plus Flex Blood Glucose Monitoring System is 20 to 600 mg/dL supported by the linearity assay study above (M.1.b).
e. Analytical specificity:
Interference studies were performed by spiking endogenous and exogenous substances into venous whole blood. Each potential interferent was tested with 3 test strip lots at 2 glucose levels (70 and 300 mg/dL) for a total of 96 samples (12 replicates per lot per
8
{8}
interferent level). Results of test samples measured on the OneTouch Ultra Plus Flex Blood Glucose Meter System were compared to the mean of the control sample measured on the OneTouch Ultra Plus Flex Blood Glucose Meter System and the bias calculated. Significant interference is defined by the sponsor as a bias within $\pm 10\%$ compared to a control sample.
The sponsor claims no significant interference for the substances and concentrations shown in the table below:
| Substance | Highest Concentration tested with no observed interference |
| --- | --- |
| Acetaminophen | 10.89 mg/dL |
| Ascorbic acid | 6.38 mg/dL |
| Bilirubin | 20.53 mg/dL |
| Cholesterol | 794.4 mg/dL |
| Creatinine | 31.83 mg/dL |
| Dopamine | 0.051 mg/dL |
| EDTA | 0.10 mg/dL |
| Ephedrine | 0.21 mg/dL |
| Galactose | 60.39 mg/dL |
| Gentisic Acid | 1.85 mg/dL |
| Glutathione | 92.61 mg/dL |
| Hemoglobin | 237.60 mg/dL |
| Heparin | 2.15 mg/dL |
| Ibuprofen | 50.52 mg/dL |
| Icodextrin | 1241.72 mg/dL |
| Lactose | 4.25 mg/dL |
| L-Dopa (Levo-Dopa) | 1.01 mg/dL |
| Maltose | 363.60 mg/dL |
| M-Dopa (Methyl-Dopa) | 1.50 mg/dL |
| Salicylic Acid | 58.90 mg/dL |
| Tetracycline | 1.52 mg/dL |
| Tetracycline | 0.001 mg/dL |
| Tetracycline | 0.001 mg/dL |
| Tetracyclines | 0.001 mg/dL |
| Tetracyclines | 0.001 mg/dL |
| Tetracyclines | 0.001 mg/dL |
{9}
| Tolazamide | 15.03 mg/dL |
| --- | --- |
| Tolbutamine | 65.98 mg/dL |
| Triglycerides | 3431.11 mg/dL |
| Urea | 297.55 mg/dL |
| Uric Acid | 8.10 mg/dL |
The sponsor lists the following limitations in the Owner’s Manual and the Test Strip Insert:
- The OneTouch Ultra Plus Flex™ Blood Glucose Monitoring System should not be used within 24 hours of receiving a D-xylose absorption test as it may cause inaccurately high results.
- Do not use the OneTouch Ultra® Plus Flex™ Blood Glucose Meter when PAM (Pralidoxime) is known or suspected to be in the whole blood sample.
- If you have medical conditions that are associated with high uric acid level or hyperuricemia (e.g. gout), then please check with your Doctor before using the One Touch Ultra Plus Flex Blood Glucose Monitoring System. Uric acid at concentrations greater than 8.0 mg/dL can interfere with glucose measurements.
- If you take drugs containing acetaminophen (e.g Tylenol etc.) or Dopamine at doses higher than the recommended high therapeutic level, then you may obtain inaccurate readings from the OneTouch Ultra Plus Flex blood glucose monitoring system. Please check with your Doctor if you are unsure.
f. Assay cut-off:
N/A
2. Comparison studies:
a. Method comparison with predicate device:
To assess system accuracy, results from the OneTouch Ultra Plus Flex Blood Glucose Monitoring System were compared to a reference method (YSI). Capillary fingerstick and venous whole blood samples were obtained by professional users from 113 participants with glucose concentrations ranging from 36.7-507.3 mg/dL. To obtain extreme blood glucose concentrations, 6 samples were altered. Testing was done using 6 meters and 3 test strip lots tested in duplicate. Results of the first test from each participant are shown below:
{10}
For glucose concentrations $< 75\mathrm{mg / dL}$
| Within ± 5 mg/dL | Within ± 10 mg/dL | Within ± 15 mg/dL |
| --- | --- | --- |
| 12/20 (60.0%) | 18/20 (90.0%) | 20/20 (100%) |
For glucose concentrations $>75\mathrm{mg / dL}$
| Within ± 5 % | Within ± 10 % | Within ± 15 % | Within ± 20 % |
| --- | --- | --- | --- |
| 58/93 (62.4%) | 83/93 (89.2%) | 92/93 (98.9%) | 93/93 (100%) |
# Linear regression analysis
| Slope | Intercept | R2 | N | Glucose Concentration range (new meter) (mg/dL) |
| --- | --- | --- | --- | --- |
| 1.02 | -2.16 | 0.99 | 113 | 36.7 – 507.3 |
b. Matrix comparison:
N/A
3. Clinical studies:
a. Clinical Sensitivity:
N/A
b. Clinical specificity:
N/A
c. Other clinical supportive data (when a. and b. are not applicable):
User performance study
To assess the performance of the OneTouch Ultra Plus Flex Blood Glucose Monitoring System in the hands of the intended users, the sponsor performed a study with 169 lay user participants at 4 clinical sites who collected and tested samples from their own fingertip. Results were analyzed by comparing capillary whole blood glucose results obtained by the lay users with the OneTouch Ultra Plus Flex Blood Glucose Monitoring System against results obtained with the same fingerstick blood samples from
{11}
the same patients analyzed by a laboratory reference method (YSI). The glucose concentrations in the samples ranged from 49.4 to 571.8 mg/dL as measured by the laboratory reference method. Results are summarized in the tables below:
For glucose concentrations < 75 mg/dL
| Within ± 5 mg/dL | Within ± 10 mg/dL | Within ± 15 mg/dL |
| --- | --- | --- |
| 15/20
(75.0%) | 18/20
(90.0%) | 19/20
(95.0%) |
For glucose concentrations > 75 mg/dL
| Within ± 5 % | Within ± 10 % | Within ± 15 % | Within ± 20 % |
| --- | --- | --- | --- |
| 94/149
(63.1%) | 132/149
(88.6%) | 143/149
(96.0%) | 149/149
(100%) |
Linear regression analysis
| Slope | Intercept | R² | N | Glucose Concentration range (new meter) (mg/dL) |
| --- | --- | --- | --- | --- |
| 1.02 | -1.29 | 0.99 | 169 | 49.4 – 571.8 |
Usability Study:
A usability study was performed to assess the readability of the labeling. 99 lay users were provided the owner's manual for 4-6 days at home prior to completing a system use evaluation (under study staff observation) followed by a questionnaire designed to evaluate the ease of use of the device and the clarity of the English language labeling. The responses to the Instructions for Use Questionnaire met the acceptance criteria, with lay users demonstrating acceptable levels of comprehension of the user manual and the strip insert. The readability of the labeling using a Flesch-Kincaid analysis was found to be: OneTouch Ultra Plus Flex Owners Booklet (7.7); OneTouch Ultra Plus Test Strip Insert (7.6) and OneTouch Ultra Plus Control Solution Insert (6.9).
4. Clinical cut-off:
N/A
5. Expected values/Reference range:
The sponsor lists the following expected blood glucose levels for non-pregnant people
{12}
without diabetes:
| Time | Range (mg/dL) |
| --- | --- |
| Fasting | Less than 100 |
| 2 hours after meals | Less than 140 |
Source: American Diabetes Association, Standards of Medical Care in Diabetes, Diabetes Care Vol. 38, Supplement 1, S1-S94, January 2015
N. Instrument Name:
OneTouch Ultra Plus Flex Blood Glucose Meter
O. System Descriptions:
1. Modes of Operation:
Does the applicant’s device contain the ability to transmit data to a computer, webserver, or mobile device?
Yes ☐ X ☐ or No ☐
Does the applicant’s device transmit data to a computer, webserver, or mobile device using wireless transmission?
Yes ☐ X ☐ or No ☐
2. Software:
FDA has reviewed applicant’s Hazard Analysis and software development processes for this line of product types:
Yes ☐ X ☐ or No ☐
3. Specimen Identification:
There is no sample identification function with this device. Samples are applied directly to the test strip as they are collected.
4. Specimen Sampling and Handling:
The system is intended to be used with capillary whole blood from fingerstick only. No alternative site testing. The whole blood sample is applied directly to the test strip by capillary action.
13
{13}
14
5. Calibration:
The OneTouch Ultra Plus Flex Blood Glucose Monitoring System is calibrated such that the result displayed is equivalent to the glucose level in a plasma sample. Calibration is automatic. There is no user input for coding.
6. Quality Control:
Glucose control solutions at two different concentrations can be run with this device. Recommendations on when to test the control materials are provided in the labeling. An acceptable range for each control level is printed on the control solutions vial label. The user is cautioned not to use the meter and to contact customer support if the control result falls outside these ranges.
P. Other Supportive Instrument Performance Characteristics Data Not Covered In The "Performance Characteristics" Section above:
1. Hematocrit Study:
To evaluate the effect of hematocrit on the OneTouch Ultra Plus Flex Blood Glucose Monitoring System, venous blood samples with hematocrit levels of 19%, 30%, 42%, 50%, and 61% were tested at 6 glucose concentrations (40±5, 65±5, 90±5, 120±6, 350±17, and 560±28 mg/dL). The evaluation included 8 meters, each tested with 2 replicates for 3 lots of test strips for a total of 864 measurements per hematocrit level. Results from the meter were compared to results obtained using a laboratory-based reference method (YSI). The evaluation of percent bias relative to YSI demonstrated acceptable performance across the hematocrit range of 20-60%.
2. Altitude study
To evaluate the effect of altitude on the OneTouch Ultra Plus Flex Blood Glucose Monitoring System, meters were tested at 2 altitudes above sea level (0 ft and 10,000 ft). Venous whole blood samples spiked at 3 glucose levels (70, 240, and 450 mg/dL) were tested at each altitude. The evaluation included 16 meters and 3 test strip lots. Each lot included 2 replicates for a total of 288 measurements per test strip lot. Results were compared to results obtained using a laboratory-based reference method (YSI) and demonstrated that altitudes up to 10,000 feet above sea level have no significant effect on blood glucose measurements from the OneTouch Ultra Plus Flex Blood Glucose Monitoring System.
3. Sample Volume:
To demonstrate the minimum sample volume, 0.2, 0.3, 0.4, and 0.5μL of venous whole blood samples at glucose concentrations of 65 and 450 mg/dL were tested. Testing included 6 replicates from 3 test strip lots for each glucose concentration/sample volume combination for a total of 240 measurements per test strip lot. 1 meter was used during testing. Values obtained were compared to values
{14}
obtained using a laboratory-based reference method (YSI). Results support a minimum sample volume of 0.4 µL.
4. Operating Conditions Study:
Temperature and humidity operating conditions were evaluated for temperatures ranging from 41°F to 113°F (5°C to 45°C) and relative humidity between 10 and 90% R.H. using 5 glucose concentration levels of venous whole blood (65, 150, 240, 350, and 450 mg/dL), 6 meters, and 3 lots of test strips over 11 days for a total of 540 measurements per glucose concentration. Individual glucose measurements were compared to the reference method (YSI) and percent bias were calculated. Results demonstrated that glucose measurements on the OneTouch Ultra Plus Flex Blood Glucose Monitoring System were not affected at temperatures ranging from 50°F to 104°F (10°C to 40°C) and relative humidity between 10 to 90% R.H. If the operating temperature is outside of these conditions, the meter displays an error message instead of a blood glucose value.
5. Infection Control and Robustness Studies:
The device is intended for single-patient use only. Disinfection efficacy testing on the surface materials of the meter demonstrated complete inactivation of hepatitis B virus (HBV) with the chosen disinfectant, Clorox Germicidal Wipes, 0.55% sodium hypochlorite (EPA Registration # 67619-12). Robustness studies were also performed by the sponsor demonstrating that there was no change in performance or external materials of the meter after 3316 cleaning and 475 disinfection cycles designed to simulate 4 years of device use with a maximum frequency of cleaning at 1x/day and disinfection at 1x/week. Cleaning and disinfection durability of the OneTouch Delica Lancing Device was previously shown in k131363.
6. EMC testing was certified and a compliance certificate provided.
Q. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
R. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.
15
